<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03671967</url>
  </required_header>
  <id_info>
    <org_study_id>MOH_2018-12-25_004857</org_study_id>
    <nct_id>NCT03671967</nct_id>
  </id_info>
  <brief_title>PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)</brief_title>
  <acronym>PETERPEN</acronym>
  <official_title>Piperacillin Tazobactam Versus Meropenem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae- a Non-inferiority Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Baruch Padeh Medical Center, Poriya</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emek Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Modena and Reggio Emilia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tel Aviv Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Meir Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Soroka University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laniado Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Chaim Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Università di Pisa, Cisanello Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universita di Verona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Milan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituti Ospitalieri di Cremona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Virgen Macarena</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jewish General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Data regarding optimal treatment for extended-spectrum beta-lactamase (ESBL) producing
      Enterobacteriaceae blood-stream infection are lacking. Observational studies show conflicting
      results when comparing treatment with combination beta-lactam-beta-lactamase inhibitor and
      carbapenems. The investigators aim to evaluate the effect of definitive treatment with
      meropenem vs. piperacillin-tazobactam on the outcome of patients with bacteremia due to
      cephalosporin-non-susceptible Enterobacteriaceae. The investigators hypothesize that
      piperacillin-tazobactam is non-inferior to meropenem.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>open-label randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 days from randomization</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment failure</measure>
    <time_frame>7 days from randomization</time_frame>
    <description>death OR fever &gt; 38°C in the last 48 hours OR lack of resolution of symptoms attributed to the focus of infection OR Sequential Failure Organ Assessment (SOFA) score increasing OR positive blood cultures by the time point assessed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>14 and 90 days from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment failure</measure>
    <time_frame>14 days and 30 days from randomization</time_frame>
    <description>death OR fever &gt; 38°C in the last 48 hours OR lack of resolution of symptoms attributed to the focus of infection OR Sequential Failure Organ Assessment (SOFA) score increasing OR positive blood cultures by the time point assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological failure</measure>
    <time_frame>7 days and 14 days from randomization</time_frame>
    <description>Repeat positive blood cultures with index pathogen on day 4 or later from randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent positive blood cultures (relapse)</measure>
    <time_frame>30 days and 90 days from randomization</time_frame>
    <description>recurrent positive blood cultures with the index pathogen after prior sterilization of blood cultures or after end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clostridium difficile associated diarrhea</measure>
    <time_frame>90 days from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically or microbiologically documented infection other than Gram-negative bacteremia</measure>
    <time_frame>90 days from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospital re-admissions</measure>
    <time_frame>90 days from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of resistance</measure>
    <time_frame>90 days from randomization</time_frame>
    <description>clinical isolates resistant to piperacillin/tazobactam and meropenem and any carbapenem-resistant bacteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carriage of carbapenemase-producing Enterobacteriaceae (CPE) and non-CPE carbapenem-resistant Enterobacteriaceae in-hospital</measure>
    <time_frame>90 days from randomization</time_frame>
    <description>detected by weekly rectal surveillance of carriage while in-hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total in-hospital days</measure>
    <time_frame>30 days and 90 days from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total antibiotic days</measure>
    <time_frame>30 days and 90 days from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>30 days from randomization</time_frame>
    <description>diarrhea, liver function test abnormalities, antibiotic rash or other immediate-type allergy, acute kidney injury defined according to RIFLE criteria</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1084</enrollment>
  <condition>Beta Lactam Resistant Bacterial Infection</condition>
  <condition>Enterobacteriaceae Infections</condition>
  <condition>Bacteremia</condition>
  <arm_group>
    <arm_group_label>piperacillin tazobactam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>meropenem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piperacillin/tazobactam</intervention_name>
    <description>4.5 grams QID</description>
    <arm_group_label>piperacillin tazobactam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem</intervention_name>
    <description>1 gram TID</description>
    <arm_group_label>meropenem</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults (age ≥ 18 years)

          2. New onset BSI due to E. coli or Klebsiella spp. in one or more blood cultures
             associated with evidence of infection.

          3. The microorganism will have to be non-susceptible to third generation cephalosporins
             (ceftriaxone and ceftazidime) and susceptible to both PTZ and meropenem (see
             microbiological methods).

          4. Both community and hospital-acquired bacteremias will be included.

          5. We will permit the inclusion of bacteremias due to E. coli or Klebsiella spp. with
             concomitant growth in blood of skin commensals considered as contaminants.

        Exclusion Criteria:

          1. More than 72 hr. elapsed since initial blood culture taken, regardless of the time
             covering antibiotics were started (up to 72 hrs.).

          2. Polymicrobial bacteremia. Polymicrobial bacteremia will be defined as either growth of
             two or more different species of microorganisms in the same blood culture, or growth
             of different species in two or more separate blood cultures within the same episode.

          3. Patients with prior bacteremia or infection that have not completed antimicrobial
             therapy for the previous infectious episode.

          4. Patients with septic shock at the time of enrollment and randomization, defined as at
             least 2 measurements of systolic blood pressure &lt; 90 mmHg and/or use of vasopressors
             (dopamine&gt;15μg/kg/min, adrenalin&gt;0.1μg/kg/min, noradrenalin&gt;0.1μg/kg/min, vasopressin
             any dose) in the 12 hours prior to randomization. In the absence of the use of
             vasopressors, a systolic blood pressure &lt;90 would need to represent a deviation for
             the patient's known normal blood pressure.

          5. BSI due to specific infections known at the time of randomization:

               1. Endocarditis / endovascular infections

               2. Osteomyelitis (not resected)

               3. Central nervous system infections

          6. Allergy to any of the study drugs confirmed by history taken by the investigator

          7. Previous enrollment in this trial

          8. Concurrent participation in another interventional clinical trial

          9. Imminent death (researcher's assessment of expected death within 48 hrs. of
             recruitment)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roni Bitterman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mical Paul, MD</last_name>
    <role>Study Director</role>
    <affiliation>Rambam Health Care Campus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leonard Leibovici, MD</last_name>
    <role>Study Director</role>
    <affiliation>Rabin Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cristina Mussini, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Modena and Reggio Emilia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roni Bitterman, MD</last_name>
    <phone>972-4-7772991</phone>
    <email>ro_oren@rambam.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mical Paul, MD</last_name>
    <phone>972-4-7772991</phone>
    <email>m_paul@rambam.health.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <zip>3435306</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roni Bitterman</last_name>
      <phone>47772991</phone>
      <email>ro_oren@rambam.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 12, 2018</study_first_submitted>
  <study_first_submitted_qc>September 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2018</study_first_posted>
  <last_update_submitted>September 16, 2019</last_update_submitted>
  <last_update_submitted_qc>September 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rambam Health Care Campus</investigator_affiliation>
    <investigator_full_name>Roni Oren MD</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>bacteremia</keyword>
  <keyword>enterobacteriaceae</keyword>
  <keyword>extended spectrum beta-lactamase</keyword>
  <keyword>meropenem</keyword>
  <keyword>piperacillin tazobactam</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Enterobacteriaceae Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Piperacillin, Tazobactam Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

